© JAN 2026 | IRE Journals | Volume 9 Issue 7 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I7-1713376

Polyherbal Formulations: A Comprehensive Review of Trending Synergistic Combinations

SHIVAM DIXIT[1], NEHA RAWAT[2], SHIKHA JAISWAL[3]
[1, 2, 3]*Dilip Kishore Mehrotra Institute of Pharmacy under the aegis of Sitapur Shiksha Sansthan, Sitapur.*

Abstract- ***Polyherbalism, the practice of combining multiple medicinal plants, represents a cornerstone of traditional medical systems worldwide, including Ayurveda, Traditional Chinese Medicine (TCM), and Kampo. This paradigm is predicated on the concept of synergy, where the therapeutic outcome of the combination is greater than the sum of the effects of its individual constituents. Driven by the resurgence of interest in natural products and the limitations of single-target, single-drug therapies for complex diseases, scientifically validated polyherbal formulations are gaining significant traction in global integrative medicine. This review systematically examines trending polyherbal formulations from major traditional systems and contemporary research. We analyse their historical context, phytochemical complexity, and proposed mechanisms of action, focusing on synergistic pharmacological interactions. A critical evaluation of preclinical and clinical evidence for their efficacy in managing prevalent conditions such as metabolic syndrome, neurodegenerative disorders, hepatotoxicity, inflammation, and immune dysregulation is presented. Furthermore, the review addresses key challenges in standardization, quality control, pharmacokinetic herb-herb interactions, and regulatory harmonization. By bridging traditional wisdom with modern scientific rigor, this article highlights the potential of polyherbal formulations as viable strategies for developing novel, multicomponent therapeutics for multifactorial diseases and underscores priorities for future research.***

Keywords: Polyherbal, Synergy, Ayurveda, Traditional Chinese Medicine, Standardization, Phytomedicine, Pharmacokinetics, Clinical Trials.

I. INTRODUCTION

The use of plants for healing is as ancient as human civilization itself. Historically, therapeutics rarely relied on isolated single herbs but employed sophisticated combinations, as documented in canonical texts like the Charaka Samhita (Ayurveda), Shennong Bencao Jing (TCM), and the works of Dioscorides (Western herbalism) [1]. This practice of polyherbalism is founded on the principle that carefully balanced mixtures can enhance efficacy, reduce toxicity, and target multiple etiological pathways of a disease simultaneously—a concept now recognized as "network pharmacology" [2].

In contrast to modern monosubstance drugs, polyherbal formulations comprise a complex matrix of primary, secondary, and synergistic phytochemicals, including alkaloids, flavonoids, terpenoids, saponins, and polyphenols. This complexity poses significant challenges for characterization but offers unique advantages for treating chronic, multifactorial conditions like diabetes, arthritis, and cognitive decline, where single-target drugs often show limited success [3].

The global nutraceutical and phytopharmaceutical market has witnessed exponential growth, with polyherbal formulations commanding a substantial share. This trend is fueled by consumer preference for natural products, increased scientific validation, and the World Health Organization's (WHO) Traditional Medicine Strategy 2014-2023, promoting integration into national health systems [4]. However, this burgeoning interest necessitates a critical, evidence-based appraisal of efficacy, safety, and quality.

This review aims to:

1. Catalog and describe scientifically trending polyherbal formulations from key traditional systems.
2. Elucidate the phytochemical and mechanistic basis of their purported synergistic actions.
3. Critically evaluate the available preclinical and clinical evidence for their therapeutic efficacy.
4. Discuss contemporary challenges in standardization, safety, and regulation.
5. Propose a future roadmap for high-quality research and development in polyherbal medicine.

© JAN 2026 | IRE Journals | Volume 9 Issue 7 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I7-1713376

II. METHODOLOGY

A comprehensive literature search was conducted using electronic databases (PubMed, Scopus, Web of Science, ScienceDirect, Cochrane Library, and specialized databases like AYUSH Research Portal) from January 2000 to March 2024. Search terms included: "polyherbal formulation," "herbal combination," "synergy," "Ayurvedic formulation," "Kampo," "TCM formula," "standardization," "clinical trial," "network pharmacology," "herb-herb interaction." Both in-vitro, in-vivo, and human clinical studies published in English were considered. References from selected articles were also screened for additional relevant publications. Formulations were selected for inclusion based on their prominence in traditional systems, volume of recent scientific literature, commercial relevance, and clinical research activity.

III. TRENDING POLYHERBAL FORMULATIONS: FROM TRADITIONAL WISDOM TO MODERN APPLICATIONS

This section details prominent formulations, categorized by their primary therapeutic indication.

3.1. Metabolic and Endocrine Disorders

- Triphala: The quintessential Ayurvedic formulation, comprising equal parts of Emblica officinalis (Amalaki), Terminalia bellirica (Bibhitaki), and Terminalia chebula (Haritaki). Traditionally a rasayana (rejuvenator) and digestive, it is now extensively researched for its anti-obesity, hypoglycemic, hypolipidemic, and antioxidant properties [5]. Synergy is attributed to the combined high vitamin C and polyphenol content from Amalaki with the laxative and lipid-lowering tannins from the Terminalia species, enhancing bioavailability and multi-target action on digestive enzymes, adipogenesis, and PPAR-γ pathways [6].
- Dia-Med/Asana (Hypoglycemic Combinations): Various patented and classical formulations like Dia-Med (containing Momordica charantia, Gymnema sylvestre, Azadirachta indica, etc.) and Asanadi Kwatha are designed for diabetes management. G. sylvestre (gurmar) suppresses sweet taste and may promote β-cell regeneration, while M. charantia (bitter melon) exhibits insulin-mimetic properties, and A. indica (neem) improves glucose uptake, offering a multi-pronged anti-diabetic approach [7].
- Jiang Tang San & Ge Gen Qin Lian Tang (TCM for Diabetes): TCM formulas for "Xiao-Ke" (wasting-thirst) syndrome. Jiang Tang San (Lycium, Ginseng, Rehmannia) focuses on Qi and Yin deficiency, showing effects on insulin sensitivity and inflammation [8]. Ge Gen Qin Lian Tang (Pueraria, Scutellaria, Coptis, Licorice) is used for damp-heat type diabetes, with components like berberine (from Coptis) having proven potent glucose-lowering effects comparable to metformin in some studies [9].

3.2. Neuroprotection and Cognitive Health

- Brahmi-Ghrita & Medhya Rasayana: Ayurvedic medicated ghee preparations and cognitive enhancers containing Bacopa monnieri (Brahmi), Centella asiatica (Mandukaparni), Convolvulus pluricaulis, and Acorus calamus. B. monnieri improves memory retention via modulation of cholinergic systems and dendrite arborization, while C. asiatica supports neuronal connectivity. Their combination is believed to enhance nervine tonic and adaptogenic effects [10].
- Yokukansan and Kami-kihi-to (Kampo): The Japanese Kampo formulation Yokukansan is extensively studied for behavioral and psychological symptoms of dementia (BPSD), Alzheimer's disease, and Lewy body dementia. Its neuroprotective effects are linked to modulation of glutamate transmission, glial cell activation, and neurotrophic factors [11]. Kami-kihi-to is used for mood disorders and fatigue, showing antidepressant-like activity.
- Kaixinsan and Bushen-Yizhi Formula (TCM for Dementia): Kaixinsan (Ginseng, Polygala, Acorus, Poria) is a classic for "heart-spleen deficiency" associated with cognitive decline. Modern studies show it reduces Aβ aggregation and tau hyperphosphorylation [12]. Bushen-Yizhi formulas (based on Rehmannia, Cornus, etc.) target "kidney essence deficiency," a TCM correlate of brain aging, influencing neurogenesis and mitochondrial function.

3.3. Hepatoprotection and Detoxification

- Liv.52®: A widely researched and marketed hepatoprotective formulation from Himalaya, containing Capparis spinosa, Cichorium intybus, Solanum nigrum, and others. It demonstrates efficacy against alcoholic and toxicant-induced liver damage, viral hepatitis, and fatty liver disease by stabilizing hepatocyte membranes, inducing antioxidant enzymes (SOD, CAT), and stimulating hepatic regeneration [13].
- Phyllanthus amarus and Tinospora cordifolia Combinations: Used in hepatitis and drug-induced liver injury. P. amarus exhibits antiviral activity against Hepatitis B, while T. cordifolia (Guduchi) is a potent immunomodulator and detoxifier. Their combination provides both direct antiviral and host-mediated hepatoprotective support [14].
- Chaihu Shugan San & Yigan Decoction (TCM): Chaihu Shugan San (Bupleurum, Citrus, Peony) is a classic "Liver-Qi Stagnation" formula, relevant in stress-related and non-alcoholic fatty liver disease (NAFLD), modulating inflammatory cytokines and lipid metabolism [15]. Yigan Decoction is used for chronic hepatitis B.

3.4. Anti-inflammatory, Immunomodulatory, and Adaptogenic Formulations

- Triphala Guggulu & Yogaraj Guggulu: Ayurvedic formulations combining Triphala with the oleo-gum resin Commiphora wightii (Guggulu). Guggulu possesses potent anti-inflammatory and lipid-lowering properties (guggulsterones). Triphala Guggulu is used for arthritis, obesity, and hyperlipidemia, where the anti-inflammatory effects of guggulu synergize with the digestive and antioxidant actions of Triphala [16].
- Curcumin-Piperine-Boswellia Synergy: A modern, evidence-based combination. Curcumin (from Curcuma longa) is a powerful but poorly bioavailable anti-inflammatory. Piperine (from Piper nigrum) inhibits metabolic glucuronidation, enhancing curcumin bioavailability by up to 2000% [17]. Boswellia serrata (Shallaki) adds anti-arthritic and anti-inflammatory 5-LOX inhibition, creating a potent natural anti-arthritic complex.
- Ashwagandha-Shatavari Combinations: Classic Ayurvedic rasayanas for stress (adaptogens) and vitality. Withania somnifera (Ashwagandha) modulates the HPA axis and GABAergic activity, reducing cortisol. Asparagus racemosus (Shatavari) is an estrogenic adaptogen and galactagogue. Together, they support adrenal and reproductive health, particularly in stress-related fatigue and female hormonal imbalance [18].
- Juzentaihoto and Hochuekkito (Kampo for Immunity): These Kampo formulas are renowned as "Kampo immunostimulants." Juzentaihoto is used for cancer patients undergoing chemotherapy to improve leukocyte counts, quality of life, and immune function via modulation of cytokines and hematopoietic factors [19]. Hochuekkito is used for chronic fatigue and recovery from illness.

IV. MECHANISMS OF ACTION: DECIPHERING SYNERGY

The efficacy of polyherbal formulations transcends the additive effects of individual herbs, rooted in complex, multi-target synergistic interactions.

4.1. Pharmacodynamic Synergy

- Multi-Target Engagement: A single herb contains multiple active compounds acting on different targets. In a formulation, this network expands exponentially. For example, in a diabetic formulation, one compound may inhibit intestinal α-glucosidase, another may stimulate insulin secretion, a third may enhance peripheral glucose uptake, and a fourth may protect pancreatic β-cells from apoptosis [20].
- Signal Pathway Modulation: Formulations often modulate entire signaling cascades. Triphala, for instance, has been shown to simultaneously influence Nrf2 (antioxidant), NF-κB (inflammatory), and PPAR-γ (metabolic) pathways, addressing oxidative stress, inflammation, and insulin resistance in metabolic syndrome [6].
- Systems Biology and Network Pharmacology: This modern approach maps the "compound-target-pathway-disease" network. It visualizes how the phytochemicals in a formulation like Yokukansan interact with a network of dementia-related targets (NMDA receptors, serotonin transporters, neurotrophic factors), providing a

systems- level understanding of its therapeutic effect [21].

4.2. Pharmacokinetic Synergy

This is crucial for enhancing bioavailability and tissue distribution.

- Bioavailability Enhancement: Piperine in Trikatu (a digestive Ayurvedic blend of pepper, long pepper, ginger) is a classic bioenhancer. It inhibits cytochrome P450 enzymes and drug efflux pumps like P-glycoprotein (P-gp), thereby increasing the plasma concentration of co-administered compounds from other herbs [22].
- Improved Solubility: Saponins from herbs like Glycyrrhiza glabra (Licorice) can act as natural surfactants, increasing the aqueous solubility of lipophilic compounds from partner herbs [23].
- Tissue Distribution and Metabolism: Certain herb combinations can alter the metabolic fate of active constituents, prolonging their half-life or directing them to specific tissues.

4.3. Reduction of Toxicity (Mitigation of Adverse Effects)

A core tenet of traditional formulation is to use adjuvant herbs (anupana) to counteract the potential side effects of primary herbs. For example, the gastrointestinal irritant potential of Boswellia may be mitigated by demulcent herbs like licorice. In TCM, licorice is famously used to "harmonize" a formula and reduce toxicity [24].

V. CRITICAL APPRAISAL OF CLINICAL EVIDENCE

While thousands of studies exist, the quality is heterogeneous. This section highlights key robust trials and systematic reviews.

- Metabolic Health: A 2018 randomized controlled trial (RCT) on Triphala in obese individuals showed significant reductions in body weight, waist circumference, and LDL cholesterol compared to placebo [25]. A meta-analysis of Jiang Tang San adjunct therapy in type 2 diabetes concluded it effectively improved HbA1c and fasting blood glucose with a good safety profile [26].
- Neurocognitive Disorders: Multiple RCTs and open-label studies support Yokukansan for reducing agitation and aggression in dementia patients. A 2020 systematic review found "promising but preliminary" evidence for Bacopa monnieri combinations in age-associated cognitive decline, calling for larger, longer- term trials [27].
- Hepatoprotection: A double-blind RCT on Liv.52® in patients with alcoholic liver disease demonstrated significant improvement in liver function tests (ALT, AST) and reduction in fatty infiltration on ultrasound compared to placebo [28].
- Inflammation and Arthritis: Several RCTs have shown that standardized Boswellia- Curcumin combinations are as effective as non-steroidal anti-inflammatory drugs (NSAIDs) in reducing pain and improving function in osteoarthritis of the knee, with a superior safety profile [29].
- Oncology Support: Clinical studies on Juzentaihoto in cancer patients receiving chemotherapy consistently report benefits in reducing myelosuppression, improving appetite, and stabilizing body weight, leading to better tolerance of treatment [30]. Limitations of Current Evidence: Common issues include small sample sizes, short duration, lack of rigorous standardization of test material, variability in control interventions (placebo vs. active), and inadequate reporting of adverse events. High-quality, multi-center, dose-finding RCTs with phytochemically characterized products are still needed for most formulations.

VI. CHALLENGES AND FUTURE PERSPECTIVES

6.1. Standardization and Quality Control

The biggest hurdle for global acceptance. Batch-to-batch variability due to geographical, seasonal, and processing differences is significant. Future work must move beyond marker compound analysis to:

- Chemometric Profiling: Using techniques like HPTLC, HPLC-MS, and NMR to generate chemical fingerprints for each formulation batch [31].

- Biological Standardization: Coupling chemical data with consistent in-vitro biological activity (e.g., antioxidant capacity, enzyme inhibition) to ensure therapeutic consistency.

6.2. Safety, Herb-Drug Interactions, and Pharmacovigilance

Polyherbal formulations are not inherently risk-free.

- Contamination: Risks include heavy metals, pesticides, microbial toxins, and adulteration with pharmaceuticals.
- Herb-Drug Interactions (HDIs): Potent cytochrome P450 or P-gp modulators in herbs (e.g., St. John's Wort, Schisandra) can dramatically alter the pharmacokinetics of co-administered drugs like anticoagulants, antiretrovirals, or immunosuppressants [32]. Systematic HDI screening for trending formulations is imperative.
- Robust Pharmacovigilance Systems: Post-marketing surveillance specific to herbal products is underdeveloped in many countries and needs strengthening.

6.3. Regulatory Harmonization

A fragmented global landscape exists. The EU's Traditional Herbal Medicinal Products Directive (THMPD), the US FDA's Dietary Supplement Health and Education Act (DSHEA), and India's AYUSH regulations differ vastly in requirements for proof of efficacy, safety, and quality. International dialogue towards harmonized guidelines is essential [33].

6.4. Future Research Directions

- Advanced Analytical and "Omics" Technologies: Integrate metabolomics, transcriptomics, and proteomics to understand the systems-level response to polyherbal therapy [34].
- Gut Microbiome Axis: Many herbs are prebiotics. Research must explore how formulations like Triphala modulate the gut microbiota to produce therapeutic metabolites (e.g., short-chain fatty acids, urolithins) and influence gut-brain, gut-liver, and gut-immune axes [35].
- Personalized Polyherbal Medicine: Leveraging pharmacogenomics to predict individual responses and optimize formulation selection based on genetic and metabolic phenotypes.
- Development of "Network-Nostics": Biomarker panels that can predict and monitor response to multi-target, network-modifying polyherbal therapies.

VII. CONCLUSION

Trending polyherbal formulations represent a rich, underexplored frontier for drug discovery and integrative healthcare. Rooted in centuries of empirical observation, they are now being deconstructed by modern science to reveal intricate networks of synergistic interactions.

Substantial preclinical and growing clinical evidence supports their efficacy in managing complex, chronic diseases where conventional medicine often seeks combinatorial approaches. However, transcending the niche of complementary medicine to achieve mainstream therapeutic acceptance requires overcoming formidable challenges in standardization, evidence generation, safety monitoring, and regulatory alignment. A concerted, interdisciplinary effort—involving ethnopharmacologists, chemists, clinicians, pharmacologists, and regulators—is crucial. By marrying the holistic paradigm of traditional systems with the rigorous analytical and experimental tools of contemporary science, polyherbal formulations can be optimized into safe, effective, and reproducible next-generation phytopharmaceuticals, offering holistic solutions for global health challenges.

REFERENCES

[1] Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional

[2] Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465-473.

[3] Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.

[4] Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12(1):122-132.

[5] World Health Organization. *WHO Traditional Medicine Strategy 2014-2023*. Geneva: World Health Organization; 2013.

[6] Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017;23(8):607-614.

[7] Baliga MS, Meera S, Mathai B, Rai MP, Pawar V, Palatty PL. Scientific validation of the ethnomedicinal properties of the Ayurvedic drug Triphala: a review. Chin J Integr Med. 2012;18(12):946-954.

[8] Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012;2(4):320-330.

[9] Tong XL, Dong L, Chen L, Zhen Z. Treatment of diabetes using traditional Chinese medicine: past, present and future. Am J Chin Med. 2012;40(5):877-886.

[10] Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes

[11] mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654.

[12] Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-326.

[13] Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005;66(2):248-252.

[14] Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive

[15] disorders. Phytother Res. 2003;17(1):1-18.

[16] Sultana S, Khan N, Sharma S, Alam A. Modulation of biochemical parameters by hepatoprotective Liv.52 in ethanol-fed rats. Ann Hepatol. 2003;2(4):216-220.

[17] Thyagarajan SP, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi MS.

[18] Herbal medicines for liver diseases in India. J Gastroenterol Hepatol. 2002;17 Suppl 3:S370-S376.

[19] Shi C, Li X, Wang X, et al. The traditional Chinese medicine formula Chaihu Shugan San ameliorates non-alcoholic fatty liver disease by regulating hepatic lipid

[20] metabolism and gut microbiota. Phytomedicine. 2022;104:154295.

[21] Sarup P, Bala S, Kamboj S. Pharmacology and Phytochemistry of Oleo-Gum Resin of Commiphora wightii (Guggulu). Scientifica (Cairo). 2015;2015:138039.

[22] Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356.

[23] Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208-213.

[24] Saiki I. A Kampo medicine "Juzen-taiho-to"--prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 2000;23(6):677-688.

[25] Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97-110.

[26] Zhao J, Jiang P, Zhang W. Molecular networks for the study of TCM pharmacology. Brief Bioinform. 2010;11(4):417-430.

[27] Atal N, Bedi KL. Bioenhancers: Revolutionary concept to market. J Ayurveda Integr Med. 2010;1(2):96-99.

[28] Fong WF, Wang C, Zhu GY, Leung CH, Yang MS, Cheung HY. Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract. Phytomedicine. 2007;14(2- 3):160-165.

[29] Wang JB, Zhao HP, Zhao YL, et al. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS One. 2011;6(9):e24498.

[30] Kamali SH, Khalaj AR, Hasani-Ranjbar S, et al. Efficacy of 'Itrifal Saghir', a

[31] combination of three medicinal plants in the treatment of obesity; A randomized controlled trial. DARU J Pharm Sci. 2012;20(1):33.

[32] Lian F, Li G, Chen X, et al. Chinese herbal medicine Jiangtang San for type 2 diabetes mellitus: a systematic review. J Tradit Chin Med. 2014;34(3):372-380.

[33] Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56-62.

[34] Gajendra, Sharma V, Sharma S, Singh L. A clinical study on the efficacy of Liv.52 in patients with alcoholic liver disease. Med Today. 1995;7:34-37.

[35] Haroyan A, Mukuchyan V, Mkrtchyan N, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized,

[36] double-blind, placebo-controlled study. BMC Complement Altern Med. 2018;18(1):7.

[37] Iizuka N, Miyamoto K, Hazama S, et al. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20

[38] adenocarcinoma. Int J Cancer. 2000;85(6):869-876.

[39] Xie PS, Leung AY. Understanding the traditional aspect of Chinese medicine in order to achieve meaningful quality control of Chinese materia medica. J Chromatogr A. 2009;1216(11):1933-1940.

[40] Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777-1798.

[41] World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. Geneva: World Health Organization; 2007.

[42] Zhang A, Sun H, Wang X. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology. 2013;57(5):2072-2077.

[43] Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179.